Last reviewed · How we verify
UMN-0501
At a glance
| Generic name | UMN-0501 |
|---|---|
| Also known as | UMN-05 |
| Sponsor | UMN Pharma Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults (PHASE2)
- Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UMN-0501 CI brief — competitive landscape report
- UMN-0501 updates RSS · CI watch RSS
- UMN Pharma Inc. portfolio CI